Organon & Co (OGN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $3.65B
Last updated: Nov 17, 2026 at 11:06 AM ET
Organon & Co (OGN) Financials: Revenue, Profit and Cash Flow
Organon reported revenue of $6.22B for the fiscal year ended Dec 31, 2025, down 2.9% from the year before. That year, net income was $187.00M with a net margin of 3.0%, operating cash flow was $700.00M and free cash flow was $538.00M. The quarter ended Sep 30, 2026 had revenue of $1.57B and net income of $164.00M.
Revenue and Margins
The operating margin was 13.3% in the fiscal year ended Dec 2025, the lowest of the 9 years shown. Over the 8 years to Dec 2025, revenue fell from $10.50B, a compound annual decline of 6.3%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $6.22B | -2.9% | 53.3% | 13.3% | 3.0% |
| Dec 2024 | $6.40B | +2.2% | 58.0% | 21.5% | 13.5% |
| Dec 2023 | $6.26B | +1.4% | 59.8% | 20.1% | 16.3% |
| Dec 2022 | $6.17B | -2.1% | 62.8% | 25.4% | 14.9% |
| Dec 2021 | $6.30B | -3.5% | 61.9% | 28.4% | 21.4% |
| Dec 2020 | $6.53B | -16.0% | 67.6% | 42.7% | 33.1% |
| Dec 2019 | $7.78B | -20.5% | 70.8% | 48.4% | 41.4% |
| Dec 2018 | $9.78B | -6.9% | 52.0% | 27.7% | 22.0% |
| Dec 2017 | $10.50B | N/A | 56.3% | 31.2% | 17.2% |
Income Statement
In the fiscal year ended Dec 2025, net income fell 78.4% from the year before. In the quarter ended Sep 2026, net income rose 2.5% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.22B | $6.40B | $6.26B | $6.17B | $6.30B | $6.53B | $7.78B | $9.78B | $10.50B |
| Cost of revenue | $2.90B | $2.69B | $2.52B | $2.29B | $2.40B | $2.12B | $2.27B | $4.69B | $4.59B |
| Gross profit | $3.31B | $3.71B | $3.75B | $3.88B | $3.90B | $4.41B | $5.50B | $5.08B | $5.91B |
| Research and development | $372.00M | $550.00M | $536.00M | $578.00M | $443.00M | $210.00M | $220.00M | $365.00M | $355.00M |
| Operating income | $824.00M | $1.37B | $1.26B | $1.57B | $1.79B | $2.79B | $3.76B | $2.71B | $3.27B |
| Net income | $187.00M | $864.00M | $1.02B | $917.00M | $1.35B | $2.16B | $3.22B | $2.15B | $1.80B |
| EBITDA | $1.29B | $1.60B | $1.44B | $1.76B | $1.98B | $2.89B | $4.03B | $4.38B | $5.08B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.57B | $1.56B | $1.46B | $1.51B | $1.60B | $1.59B | $1.51B | $1.59B | $1.58B | $1.61B | $1.62B | $1.60B |
| Gross profit | $869.00M | $847.00M | $783.00M | $741.00M | $857.00M | $874.00M | $841.00M | $896.00M | $923.00M | $939.00M | $957.00M | $915.00M |
| Operating income | $365.00M | $322.00M | $235.00M | -$91.00M | $358.00M | $324.00M | $233.00M | $288.00M | $339.00M | $371.00M | $376.00M | $254.00M |
| Net income | $164.00M | $108.00M | $146.00M | -$205.00M | $160.00M | $145.00M | $87.00M | $109.00M | $359.00M | $195.00M | $201.00M | $546.00M |
Balance Sheet
As of Dec 2025, total debt of $8.64B exceeded cash and equivalents by $8.07B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | $12.87B | $13.10B | $12.06B | $10.96B | $10.68B | $10.11B | $10.55B | $10.49B | N/A |
| Current assets | $4.35B | $4.35B | $4.51B | $3.93B | $3.76B | $3.57B | $3.96B | $3.71B | N/A |
| Cash and equivalents | $574.00M | $675.00M | $693.00M | $706.00M | $737.00M | $12.00M | $319.00M | $244.00M | N/A |
| Total liabilities | $12.12B | $12.63B | $12.13B | $11.85B | $12.19B | $4.62B | $3.51B | $4.15B | N/A |
| Short-term debt | $16.00M | $20.00M | $9.00M | $8.00M | $9.00M | $0 | $48.00M | -$207.00M | N/A |
| Long-term debt | $8.63B | $8.86B | $8.75B | $8.90B | $9.13B | $0 | $70.00M | $34.00M | N/A |
| Shareholder equity | $752.00M | $472.00M | -$70.00M | -$892.00M | -$1.51B | $5.49B | $7.04B | $6.35B | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $13.40B | $13.18B | $13.00B | $12.87B | $13.55B | $13.50B | $13.16B | $13.10B | $12.75B | $12.15B | $11.89B | $12.06B |
| Total liabilities | $12.21B | $12.17B | $12.09B | $12.12B | $12.65B | $12.77B | $12.61B | $12.63B | $12.26B | $12.01B | $11.84B | $12.13B |
| Cash and equivalents | $1.46B | $1.13B | $1.12B | $574.00M | $672.00M | $599.00M | $547.00M | $675.00M | $763.00M | $704.00M | $575.00M | $693.00M |
| Shareholder equity | $1.19B | $1.01B | $903.00M | $752.00M | $906.00M | $733.00M | $542.00M | $472.00M | $493.00M | $144.00M | $48.00M | -$70.00M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 76.9% of operating cash flow. Dividends came to 16.4% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $700.00M | $939.00M | $799.00M | $858.00M | $2.16B | $2.28B | $3.02B | $3.69B | $3.42B |
| Capital expenditures | $162.00M | $175.00M | $251.00M | $196.00M | $192.00M | $255.00M | $92.00M | $101.00M | $86.00M |
| Free cash flow | $538.00M | $764.00M | $548.00M | $662.00M | $1.97B | $2.03B | $2.93B | $3.59B | $3.33B |
| Dividends paid | $88.00M | $297.00M | $294.00M | $290.00M | $145.00M | $0 | $0 | $145.00M | N/A |
| Investing cash flow | -$390.00M | -$513.00M | -$260.00M | -$420.00M | -$481.00M | -$250.00M | -$88.00M | -$69.00M | -$56.00M |
| Financing cash flow | -$561.00M | -$368.00M | -$569.00M | -$433.00M | -$977.00M | -$2.02B | -$2.93B | -$4.16B | -$3.37B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $370.00M | $107.00M | $225.00M | $141.00M | $264.00M | $220.00M | $75.00M | $390.00M | $141.00M | $332.00M | $76.00M | $397.00M |
| Capital expenditures | $44.00M | $42.00M | $37.00M | $45.00M | $46.00M | $39.00M | $32.00M | $55.00M | $42.00M | $32.00M | $46.00M | $79.00M |
| Free cash flow | $326.00M | $65.00M | $188.00M | $96.00M | $218.00M | $181.00M | $43.00M | $335.00M | $99.00M | $300.00M | $30.00M | $318.00M |
Frequently Asked Questions About OGN
What is Organon's annual revenue?
Organon reported revenue of $6.22B for the fiscal year ended Dec 31, 2025.
How fast is Organon's revenue growing?
Revenue was down 2.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 0.2%.
Is Organon profitable?
Yes. Organon reported net income of $187.00M for the fiscal year ended Dec 31, 2025, with a net margin of 3.0%.
How much free cash flow does OGN generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $700.00M minus capital expenditures of $162.00M produced free cash flow of $538.00M.
How much debt does Organon have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $8.63B, short-term debt of $16.00M and cash and equivalents of $574.00M.
OGN pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors